FDA approves new therapy; Revolution Medicines in spotlight as its pancreatic cancer treatment advances patient survival.
Recent reporting shows targeted drugs, immunotherapies and refined radiochemotherapy are prolonging life for cancer patients. Trials indicate higher survival in younger groups and expanding use of genomic profiling. New therapies are pairing with existing treatments to push back relapse and increase quality of life, though access and long-term outcomes vary.
Pharma licensing assets from China has become the main source for Western drug developers, with Evaluate projecting China-based deals will exceed two-thirds of industry value this year. The shift prompts concerns about hollowing out U.S. biotech capacity while supporters argue it accelerates patient access to new medicines.
The FDA has approved daraxonrasib, sold as Rasonque, for patients with metastatic pancreatic cancer whose disease has progressed after chemotherapy. A 500‑patient trial has shown median overall survival of 13.2 months on the drug versus 6.7 months on chemotherapy. The oral pill targets multiple KRAS mutations and will be marketed by Revolution Medicines.